Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Thumbnail image for IMD-7-1949
Case
-
Reference no. IMD-7-1949
Compact case
Published by:
IMD (2018)
Version:
06.02.2018
Revision date:
13-Mar-2018
Length:
2 pages
Data source:
Field research

Abstract

AM-Pharma is a biotech company developing a medicine for patients with acute kidney injury. The case describes the company's journey from inception in 2001 to a large deal with Pfizer in 2015. The aim is to discuss the value creation of AM-Pharma through its strategic decisions over time. It highlights the patient journey, company challenges, market size potential, and how the management team was able to raise multiple financing rounds from venture capitalists. It further provides the readers with a unique insight in the key risks and operational challenges of a biotech company and the value of an experienced management team backed by strong investors. The drug development process is inherently risky, long and expensive and the probability of commercializing a new drug is very low. The company's CEO is the protagonist and the case is split in three parts to provide the readers with surprises and open strategic questions which are time related. The case is semi-chronologically and a patient story is intermingled to provide a different perspective on clinical trials, ethical dilemmas and the high unmet medical need for new therapies. The case ends with a valuation simulation, in which the readers can negotiate the AM-Pharma/Pfizer deal themselves.

Topics

Strategy; Value creation; Biotechnology; Entrepreneur; Start-up; Venture capital; Deal; Negotiation; Mergers and acquisitions
Locations:
Size:
Start-up, no revenue, 14 team members - 8 full time equivalent
Other setting(s):
2001-2015

Access this item

casecent.re/p/150843
View our pricing guide
or to see prices.

Reviews & usage